Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Product Performance of a Toric Contact Lens

Not Applicable

Completed

Conditions: Myopia
Astigmatism

Interventions: Device: SofLens DD Toric
Device: Ciba Vision Focus Dailies Toric Contact Lens

First Posted Date: 2008-04-16

Last Posted Date: 2011-12-12

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 220

Registration Number: NCT00658996

Locations: 🇲🇾
Laser Focus Sdn Bhd, Vision Correction Centre, Johor Bahru, Malaysia

Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a New Packaging Configuration

Not Applicable

Completed

Conditions: Comfort

Interventions: Device: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
Device: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.

First Posted Date: 2008-04-16

Last Posted Date: 2011-12-12

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 312

Registration Number: NCT00659815

Locations: 🇺🇸
James Ferrari, OD, Rochester, New York, United States

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

Phase 3

Completed

Conditions: Ocular Inflammation

Interventions: Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment
Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment

First Posted Date: 2008-03-28

Last Posted Date: 2015-03-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 400

Registration Number: NCT00645671

Locations: 🇺🇸
John Hunkeler, MD, Overland Park, Kansas, United States

Comparative Performance of PureVision, Acuvue Oasys and O2Optix

Phase 4

Completed

Conditions: Myopia

Interventions: Device: PureVision Contact Lens
Device: Acuvue Oasys Contact Lens
Device: O2Optix Contact lens

First Posted Date: 2008-03-21

Last Posted Date: 2011-12-12

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 510

Registration Number: NCT00640341

Locations: 🇺🇸
Anderson & Associates, Tampa, Florida, United States

Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution

Not Applicable

Completed

Conditions: Contact Lens Solutions

Interventions: Device: Bausch & Lomb Multipurpose Solution - No Rub Care
Device: Bausch & Lomb Multipurpose Solution - Rub Care
Device: Ciba Vision Aquify Multipurpose Solution

First Posted Date: 2008-03-14

Last Posted Date: 2015-03-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 541

Registration Number: NCT00636363

Locations: 🇺🇸
Place Eye Care, LeRoy, New York, United States

Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon OptiFree Replenish Multipurpose Solution

Not Applicable

Completed

Conditions: Adverse Effect of Contact Lens Solution

Interventions: Device: Bausch & Lomb Multipurpose Solution
Device: Alcon OptiFree Replenish Multipurpose Solution

First Posted Date: 2008-03-14

Last Posted Date: 2011-12-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 361

Registration Number: NCT00636194

Locations: 🇲🇾
Laser Focus Sdn Bhd, Vision Correction Centre, Jalan Kuning, Tamn Pelangi, Johor Bahru, Malaysia

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

Phase 2

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Vehicle
Drug: ISV-403

First Posted Date: 2008-02-25

Last Posted Date: 2015-03-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 270

Registration Number: NCT00622908

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Phase 2

Completed

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Latanoprost 0.005%
Drug: PF-03187207
Drug: PF-03187207 Vehicle
Drug: Latanoprost Vehicle

First Posted Date: 2008-01-16

Last Posted Date: 2020-09-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 117

Registration Number: NCT00595101

Locations: 🇯🇵
Pfizer Investigational Site, Shizuoka, Japan

Efficacy and Safety of Bromfenac Ophthalmic Solution

Phase 2

Completed

Conditions: Cataract Surgery

Interventions: Drug: bromfenac ophthalmic solution

First Posted Date: 2008-01-04

Last Posted Date: 2013-02-15

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 568

Registration Number: NCT00585975

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Bepreve
Drug: Placebo

First Posted Date: 2008-01-04

Last Posted Date: 2013-02-15

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 861

Registration Number: NCT00586625

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy